OK, what would you like to talk about? How many times can we repeat the same stuff we already know about Ponatinib, Ridaforolimus, and the yet to be in clinical trial, AP26113? Until Ariad actually starts producing some news via medical conferences or partnerships or whatever, ARIA stock is a victim of the macro-global economics...which is relevant IMO to the way this pig is trading. (because regardless of what ARIA has in the pipe, if the macro-global markets go to hell and funds drop equities across the board, ARIA will not be spared in the slightest bit)
